1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Lupus Vasculitis, Central Nervous System: new trials by email Literature Review of Lupus Vasculitis, Central Nervous System trials Research Report on Lupus Vasculitis, Central Nervous System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study Placebo, EG-501 - Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE) | Phase 2 | Completed | Evergreen Therapeutics, Inc. | 131 | 2018-08-23 | 2025-12-15 |
Cognitive Dysfunction (1) · Lupus Erythematosus, Systemic (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Central Nervous System Viral Diseases (1) · Cerebrovascular Disorders (1) · Cognition Disorders (1) · Connective Tissue Diseases (1) · Encephalitis (1) · Immune System Diseases (1) · Infections (1) · Meningitis (1) · Meningoencephalitis (1)
Evergreen Therapeutics, Inc. (1)
United States (1)